Extended Data Fig. 7: aPKC inhibitor dose–response experiments in mouse, cow and human embryos.
From: Initiation of a conserved trophectoderm program in human, cow and mouse embryos
a, Schematic of aPKC inhibitor treatment in mouse embryos. b, Immunofluorescence analysis of GATA3, E-cadherin, YAP1 and DAPI nuclear staining in mouse morula embryos treated with different concentrations of aPKC inhibitor (n = reported in Supplementary Table 6 for each condition). c, Schematic of aPKC inhibitor treatment in cow embryos. d, Immunofluorescence analysis of β-catenin, YAP1 and DAPI nuclear staining in cow morula embryos treated with different concentrations of aPKC inhibitor (n = reported in Supplementary Table 7 for each condition). e, Schematic of aPKC inhibitor treatment in human embryos. f, Immunofluorescence analysis of GATA3, β-catenin, YAP1 and DAPI nuclear staining in human morula embryos treated with different concentrations of aPKC inhibitor (n = reported in Supplementary Table 8 for each condition). Scale bars, 25 μm (mouse embryos), 50 μm (cow and human embryos). More details about statistics and reproducibility are provided in Methods.
